These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20010576)

  • 1. Medicare formulary coverage for top-selling biologics.
    Liang SY; Haas JS; Phillips KA
    Nat Biotechnol; 2009 Dec; 27(12):1082-4. PubMed ID: 20010576
    [No Abstract]   [Full Text] [Related]  

  • 2. Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006.
    Bowman J; Rousseau A; Silk D; Harrison C
    Health Aff (Millwood); 2006; 25(5):1240-8. PubMed ID: 16966719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coverage for hepatitis C drugs in Medicare Part D.
    Jung JK; Feldman R; Cheong C; Du P; Leslie D
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.
    Tseng CW; Dudley RA; Chen R; Walensky RP
    JAMA Netw Open; 2020 Apr; 3(4):e202739. PubMed ID: 32286656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies.
    Egilman AC; Wallach JD; Dhruva SS; Gonsalves GS; Ross JS
    J Gen Intern Med; 2019 Nov; 34(11):2319-2321. PubMed ID: 31313117
    [No Abstract]   [Full Text] [Related]  

  • 8. PDPs see increases in cost-sharing amounts.
    Manag Care; 2009 Aug; 18(8):55. PubMed ID: 19731513
    [No Abstract]   [Full Text] [Related]  

  • 9. The great debate part II: should managed care rely on cost sharing to manage big-ticket biologics?
    Zitter M
    Am J Manag Care; 2006 Apr; 12(6 Suppl):S153-8; discussion S167-72; quiz S173-6. PubMed ID: 16613529
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.
    Erath A; Dusetzina SB
    JAMA Netw Open; 2020 Apr; 3(4):e203969. PubMed ID: 32338754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug cost-sharing amounts stable 2010-2011.
    Manag Care; 2012 Jan; 21(1):59. PubMed ID: 22334940
    [No Abstract]   [Full Text] [Related]  

  • 12. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.
    Doshi JA; Li P; Huo H; Pettit AR; Kumar R; Weiss BM; Huntington SF
    Am J Manag Care; 2016 Mar; 22(4 Suppl):s78-86. PubMed ID: 27270157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specialty Drugs - A Distinctly American Phenomenon.
    Naci H; Kesselheim AS
    N Engl J Med; 2020 Jun; 382(23):2179-2181. PubMed ID: 32492301
    [No Abstract]   [Full Text] [Related]  

  • 14. The Case for Restructuring the Medicare Prescription Drug Benefit.
    Frakt A; Miller M
    Health Serv Res; 2018 Dec; 53(6):4132-4137. PubMed ID: 30069872
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicare Part D Plans' Coverage and Cost-Sharing for Acute Rescue and Preventive Inhalers for Chronic Obstructive Pulmonary Disease.
    Tseng CW; Yazdany J; Dudley RA; DeJong C; Kazi DS; Chen R; Lin GA
    JAMA Intern Med; 2017 Apr; 177(4):585-588. PubMed ID: 28241217
    [No Abstract]   [Full Text] [Related]  

  • 16. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.
    Padula WV; Ballreich J; Anderson GF
    Appl Health Econ Health Policy; 2018 Dec; 16(6):753-763. PubMed ID: 30058011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing Medicare's Protected Classes: History, Mistrust, and Budgets in the Prescription Drug Market.
    Frank RG
    Psychiatr Serv; 2019 Oct; 70(10):858-859. PubMed ID: 31480929
    [No Abstract]   [Full Text] [Related]  

  • 18. Insurers offer more coverage to fill Part D gap.
    Manag Care; 2007 Dec; 16(12):54. PubMed ID: 18198733
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
    [No Abstract]   [Full Text] [Related]  

  • 20. The case for cost sharing for biologic therapies.
    Fish L
    Am J Manag Care; 2006 Apr; 12(6 Suppl):S159-61; discussion S167-72; quiz S173-6. PubMed ID: 16613530
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.